Last reviewed · How we verify
Meningitis due to Bacteroides — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Metro I.V. In Plastic Container | METRONIDAZOLE | Baxter | Nitroimidazole Antimicrobial [EPC] | 1963-01-01 | ||
| Metronidazol | Metronidazol | University of Oslo | Thioredoxin reductase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 1 drug in Meningitis due to Bacteroides
- University of Oslo · 1 drug in Meningitis due to Bacteroides
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Meningitis due to Bacteroides:
- Meningitis due to Bacteroides treatment updates — RSS
- Meningitis due to Bacteroides treatment updates — Atom
- Meningitis due to Bacteroides treatment updates — JSON
Cite this brief
Drug Landscape (2026). Meningitis due to Bacteroides — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/meningitis-due-to-bacteroides. Accessed 2026-06-10.
Related
- Meningitis due to Bacteroides full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing